|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/30 | |
| A61P 5/00 | |||
| A01N 37/18 |
| (11) | Number of the document | 1667521 |
| (13) | Kind of document | T |
| (96) | European patent application number | 04817764.6 |
| Date of filing the European patent application | 2004-09-09 | |
| (97) | Date of publication of the European application | 2006-06-14 |
| (45) | Date of publication and mention of the grant of the patent | 2011-12-07 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2004/029735 |
| Date | 2004-09-09 |
| (87) | Number | WO 2005/049792 |
| Date | 2005-06-02 |
| (30) | Number | Date | Country code |
| 502579 P | 2003-09-12 | US |
| (72) |
CLARK, Ross G., NZ
|
| (73) |
Tercica, Inc.,
2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005,
US
|
| (54) | METHODS FOR TREATMENT OF INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) DEFICIENCY |
| METHODS FOR TREATMENT OF INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) DEFICIENCY |